Veradigm Inc. · OTC:MDRX
Veradigm — JP Morgan Healthcare Conference 2024
31 slides from Veradigm's conference presentation, Jan 10, 2024
Slide 1: JP Morgan Healthcare Conference: Building for the Future
JP Morgan Healthcare Conference Building for the Future January 10, 2024 Exh. 99.2
Slide 2: Disclaimer & Forward-Looking Statements
Disclaimer & Forward-Looking Statements The estimated financial results contained in this presentation are preliminary, and final results for fiscal year 2023 may change. These preliminary results are based upon our estimates and are subject to completion of our financial closing procedures. In addi
Slide 3: Agenda
Agenda Introduction Leadership Team Financials Business Update
Slide 4: Our Mission
Our Mission At Veradigm we are transforming health, insightfully PAYER LIFE SCIENCES PROVIDER Veradigm is a healthcare technology and analytics company spanning across the three pillars of healthcare Differentiators are our connectivity, scale, and expertise Copyright ©2024 Veradigm® | All rights re
Slide 5: Leadership Team
Leadership Team Copyright ©2024 Veradigm® | All rights reserved 5
Slide 6: Refreshed Executive Team Driving Veradigm Forward
Refreshed Executive Team Driving Veradigm Forward Dr. Shih-Yin Ho Interim CEO Lee Westerfield Interim CFO Former Pfizer eHealth executive & CEO of multiple startups in data and healthtech Veradigm Board member Deep expertise in healthtech product innovation & transformation Vision & expertise to acc
Slide 7: Financials
Financials Copyright ©2024 Veradigm® | All rights reserved 7
Slide 8: SEC Filing Status Update
SEC Filing Status Update Copyright ©2024 Veradigm® | All rights reserved 8
Slide 9: The Financial State of Veradigm is Fundamentally Sound
Stable & Recurring Consistently Profitable Solid Capital Foundation Financial Profile The Financial State of Veradigm is Fundamentally Sound Revenue Net Cash Adjusted EBITDA and Adjusted EPS For further information, please refer to the Appendix.
Slide 10: Revenue, F2023 Estimates
Revenue, F2023 Estimates High Quality Revenue Mix with a Majority Recurring Revenue Please see disclaimer & forward-looking statements and appendix for more information. Provider, Stable Majority Recurring Revenue Payer & Life Sciences, Moderate Growth $608M to $622M 2022 2023 Growth by Segment
Slide 11: Adjusted EBITDA and EPS, F2023 Estimates
$122M to $135M Adjusted EBITDA and EPS, F2023 Estimates Steady Profitability Adjusted EBITDA $0.79 to $0.88 Adjusted EPS, Non-GAAP Basis Please see disclaimer & forward-looking statements and appendix for more information.
Slide 12: Net Cash, F2023 Estimates
Multiple Alternatives Share Repurchase Margin Expansion Invest in Product and Cloud Infrastructure Accelerate Growth Tech-Forward Strategic Acquisitions Net Cash, F2023 Estimates Clean Balance Sheet Enables Alternatives to Elevate ROI & TEV $440M+ Convertible Notes, $208M Senior Facility, Undrawn Ca
Slide 13: Business Update
Business Update Copyright ©2024 Veradigm® | All rights reserved 13
Slide 14: Veradigm Business & Growth Drivers: The Veradigm Advantage
Business Update Veradigm Business & Growth Drivers The Veradigm Advantage Our Unique Position to Lead Next Generation Health Intelligence Product Platforms Scalable, High-Quality Data Assets Provider, Payer and Life Sciences Customer Footprint Healthcare Ecosystem Expertise Leveraging AI Technology
Slide 15: Empowering clients with trusted data, insights, and solutions
We empower our clients with trusted data, insights, and solutions to help improve health outcomes and reduce costs for the patients they serve PAYER LIFE SCIENCES/RESEARCH PHYSICIANS/PROVIDERS Veradigm’s established technology platforms & solutions place it at the intersection of the three pillars o
Slide 16: Unique Ability to Drive Efficiencies at the Point of Care
Unique Ability to Drive Efficiencies; Enhance Decision Making at the Point of Care Scale Workflow Connectivity Analytics Core Veradigm Assets Proprietary Data Registries Healthcare IT Partners The Veradigm Advantage Large-Scale, High-Quality Data &
Slide 17: Market Trends Driving Veradigm's Growth
Market Trends Driving Veradigm’s Growth Key stakeholder markets are converging around value-based care, and so is Veradigm Move to outpatient and ambulatory care Changing interoperability standards Payers need data to drive value-based purchasing Dynamic regulatory environment Expanding use of real-
Slide 18: A unique and valuable dataset in healthcare
For the last 20 years, Veradigm has built a unique and valuable dataset in healthcare, positioning the company to become the health intelligence leader for the next century of care Veradigm sits at the intersection of large-scale, high-quality data that spans clinical and claims But there is more…
Slide 19: Positioned to Capitalize on AI & Lead Health Intelligence
Strategically Positioned to Capitalize on AI & Lead the Next Generation of Health Intelligence Products Our established platforms & solutions sit at the center of the three pillars of healthcare Our data capture spans large provider footprint to create high-value, scalable data assets Our data conne
Slide 20: Positioned at the center of the largest platform shift
Veradigm is positioned to be at the center of the largest platform shift ever in healthcare and life sciences because we have the data lead AI is turning Veradigm’s data assets into data opportunities by putting its platform at center of the care continuum of the future We can lead ethically to supp
Slide 21: Strategy Meets the Future
Strategy Meets the Future Q2 2022 Veradigm announces reorganization and focus on life sciences & payer markets Q1 2023 New Board appointments with industry & transformation business expertise Q2 2023 Strategy developed to harvest & monetize data, analytics, and AI for Veradigm’s data assets Q3 2023
Slide 22: Leveraging AI Capabilities to Build Product Lines
= developing Leveraging AI Capabilities to Build Product Lines of Differentiated Data & Health Intelligence Products Strategy Expand scope of data capture to fulfill product of wholistic Health Intelligence Provider EHR & EMR Data Assets Patient Data Capture Other Novel Clinical Data Sources AI-Enab
Slide 23: 2024-2026 Product and Data Platform Plan
2024 2025 2026 Supporting Current Customers and Accelerating Data Sales Value-Added Analytics Platform HCLS Intelligence Data Platform Leading with Data, AI Tech, Insights to Bring High Value Products to Providers, Payers & Life Sciences + = Ecosystem of Base Models Veradigm Data Actionable Insights
Slide 24: Veradigm. Transforming Health, Insightfully
GN ee Copyright ©2024 Veradigm® | All rights reserved veradigm. TRANSFORMING HEALTH, Insightfully
Slide 25: Appendix
Appendix Copyright ©2024 Veradigm® | All rights reserved 25
Slide 26: Non-GAAP Financial Measures
Non-GAAP Financial Measures Veradigm reports its financial results in accordance with U.S. generally accepted accounting principles, or GAAP. To supplement this information, Veradigm presents Adjusted EBITDA and non-GAAP diluted earnings per share, which are considered non-GAAP financial measures un
Slide 27: Non-GAAP Financial Measures
Non-GAAP Financial Measures Acquisition-Related Amortization. Acquisition-related amortization expense is a non-cash expense arising primarily from the acquisition of intangible assets in connection with acquisitions or investments. Veradigm excludes acquisition-related amortization expense from non
Slide 28: Bridge: Prior Guidance to Current Estimated Range
Bridge: Prior Guidance to Current Estimated Range Revenue variance reflects provider segment revenue shortfall. Estimated Range of revenue, on a GAAP basis, includes a favorable customer litigation settlement contributing approximately $16 million that reflects services provided over prior years. Ad
Slide 29: Reconciliation: Estimated Adjusted EBITDA Range
Reconciliation: Estimated Adjusted EBITDA Range
Slide 30: Reconciliation: Estimated Non-GAAP Earnings Per Share Range
Reconciliation: Estimated Non-GAAP Earnings Per Share Range
Slide 31: VETAMISM. wsrosscsin insioheany 0.00 wedgncon
r~ VETAMISM. wsrosscsin insioheany 0.00 wedgncon